Search Results: (30 results)

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

Researchers are conducting a survey of cancer patients who were diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years. The aim is to gather information about their diagnosis, treatment, and personal experiences of battling cancer. The survey will collect data on the type of cancer, diagnosis, treatment plan, medications used, and personal stories throughout the journey to help gain a better understanding of the emotional and psychological impact of cancer on patients.

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

The LiFT UP Study is a research project for individuals and families from around the world. The goal is to learn more about adults and children who have a change in the TP53 gene in their blood to better predict their specific cancer risks. 

Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis. this study to evaluate an online tool developed to educate and provide support to women and people assigned female at birth who are interested in family building after cancer. This study involves the completion of four online surveys. All study procedures are done remotely.

This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.

The purpose of this study is to get participants’ opinions on the content, format, and design of educational materials that inform about the emotional consequences of undergoing a bilateral mastectomy.

Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

This study will examine the effectiveness and safety of cemiplimab, a treatment given prior to surgery. Participants will undergo endoscopy after the therapy and take CT scans to assess the effects of the therapy. The study also will compare genes of pretreatment cancer samples between patients who responded well to the therapy and patients who did not.

Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

Survey for cancer caregivers of an LGBTQIA+ family member or friend to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors when compared to standard of care symptom management. 

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

• For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.
• People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.

This study will test the safety and effectiveness of the drug sovilnesib in patients with ovarian cancer.

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for colorectal, pancreatic or prostate cancer. You can take the survey here. 

This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation. Participants will continue to receive the medication as long as their cancer doesn’t get worse and they do not experience severe side effects.

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study. 

PreCharge is an IRB approved, nationwide study funded by the National Cancer Institute. The purpose of this study is to test a digital program designed to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being.

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA is not part of standard of care to determine if colon cancer treatment was successful or if there is a recurrence. 

This study aims to interview those who tested positive for an adult-onset cancer predisposition as a minor to highlight their attitudes regarding predispositional genetic testing in childhood. Results may help guide clinicians in how they approach and navigate conversations about genetic testing in presymptomatic minors.

Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.

* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).

This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.